A5012479598- HIV/AIDS drug development and treatment
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- HIV Research and Treatment
- Hepatitis C virus research
- HIV/AIDS Research and Interventions
- Hepatitis B Virus Studies
- SARS-CoV-2 and COVID-19 Research
- Poxvirus research and outbreaks
- Herpesvirus Infections and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Viral gastroenteritis research and epidemiology
- Pneumonia and Respiratory Infections
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Psychosomatic Disorders and Their Treatments
- Multiple Sclerosis Research Studies
- Dermatological and COVID-19 studies
- Escherichia coli research studies
- Bacillus and Francisella bacterial research
- Gastrointestinal disorders and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- COVID-19 and healthcare impacts
- Viral-associated cancers and disorders
- Clostridium difficile and Clostridium perfringens research
- Abdominal Trauma and Injuries
Ospedale Papa Giovanni XXIII
2014-2024
Ospedale San Paolo
2024
University of Milan
2024
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
2024
Azienda Ospedaliero Universitaria Ospedali Riuniti
2012
Abstract Bergamo province was badly hit by the coronavirus disease 2019 (COVID-19) epidemic. We organised a public-funded, multidisciplinary follow-up programme for COVID-19 patients discharged from emergency department or inpatient wards of ‘Papa Giovanni XXIII’ Hospital, largest public hospital in area. As 31 July, first 767 had completed post-discharge assessment. Patients entered our at median time 81 days after discharge. Among them, 51.4% still complained symptoms, most commonly...
Little is known about the applicability of dual treatments based on integrase inhibitors. We explored combination lamivudine + dolutegravir as an option when switching from standard cART in virologically suppressed patients.In this prospective cohort we enrolled patients previously switched to 3TC DTG who were 18 years or older, with no previous resistance mutations used drugs, having a HIV-RNA <50 copies/ml for 6 months longer, negative HBsAg and stable (>6 months) cART.Ninety-four...
The risk of infection associated with immunomodulatory or immunosuppressive disease-modifying drugs (DMDs) in patients multiple sclerosis (MS) has been increasingly addressed recent scientific literature. A modified Delphi consensus process was conducted to develop clinically relevant, evidence-based recommendations assist physicians decision-making relation the risks a wide range infections different DMDs MS. current statements, developed by panel experts (neurologists, infectious disease...
Thyroid dysfunctions associated with SARS-CoV-2 acute infection have been extensively described since the beginning of COVID-19 pandemics. Conversely, few data are available on occurrence thyroid autoimmunity after resolution. We assessed prevalence autoimmune disease (ATD) and in survivors three months hospital admission.Single-center, prospective, observational, cohort study performed at ASST Papa Giovanni XXIII Hospital, Bergamo, Italy. 599 were prospectively evaluated for function...
What is MASTER?What was the rationale for setting up cohort?The Italian MASTER (MAnagement Standardizzato di TErapia antiRetrovirale, standardized management of antiretroviral therapy) cohort a hospital-based multicentre, open, dynamic HIV established in mid 1990s, with retrospective patient enrolment from 1986 to 1997 and subsequent prospective recruitment.At that time, no institutional system surveillance infection available, apart registration AIDS cases.Accurate, precise up-to-date data...
Prevention of infections is crucial in solid organ transplant (SOT) candidates and recipients. These pa-tients are exposed to an increased infectious risk due previous insufficiency pharmaco-logic immunosuppression. Besides infectious-related morbidity mortality, this vulnerable group patients also the acute decompensation rejection or failure pre- post-transplant period respectively, since antimicrobial treatments less effective than immunocompetent patients. Vaccination represents a major...
On Being a Doctor5 May 2020Love in the Time of CoronaFREESimone V. Benatti, MDSimone MDHospital Papa Giovanni XXIII, Bergamo, Italy (S.V.B.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-1137 Audio Reading - "Love Corona" Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads by Simone MD Your browser does not support audio element. player progress bar Step backward current track Play trackPause forward Mute trackUnmute 00:00/ SectionsAboutVisual AbstractPDF...
We report safety and tolerability of raltegravir (RAL) as a forth HIV agent in two highly viraemic newborns. Raltegravir (6 mg/kg) was given orally twice daily. The other antiretrovirals were assumed according to standard dose for first baby born at week 36. An antiretroviral therapy consisting zidovudine, lamivudine, lopinavir/ritonavir started 96 hour after delivery. added 120, being plasma HIV-1 RNA above 10×106 copies/ml. declined 5·000 copies/ml day 30. second 40. He on nevirapine 0,...
Abstract Background Recovery from acute COVID-19 may be slow and incomplete: cases of Post-Acute Sequelae COVID (PASC) are counted in millions, worldwide. We aimed to explore if how the pre-existing Socio-economic-status (SES) influences such recovery. Methods analyzed a database 1536 consecutive patients first wave Italy (February-September 2020), previously admitted our referral hospital, followed-up dedicated multidisciplinary intervention. excluded those seen earlier than 12 weeks (the...
Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited.
The long-term effects of an intensified induction regimen are unknown. In this pilot, randomized, prospective study we evaluate the effect a short-term four-drugs in patients with high baseline viral load.Naive HIV-RNA>100.000 copies/ml receiving TDF+FTC+EFV+RAL (group ER) for 4 months and were then simplified to TDF+FTC+EFV. Two randomized control groups treated ab-initio TDF+FTC+EFV (E) or TDF+FTC+RAL (R) used.19 mean age 38 years CD4 count 334 (SD 216) cells/mcL HIV-RNA 5.47 log 0.32)...
<title>Abstract</title> <bold>BACKGROUND</bold> Recovery from acute COVID-19 may be slow and incomplete: cases of Post-Acute Sequelae COVID (PASC) are counted in millions, worldwide. We aimed to investigate how the pre-existing Socio-economic-status (SES) influences such recovery.<bold>METHODS</bold> analyzed a database 1536 consecutive patients first wave Italy (February-September 2020), previously admitted our referral hospital, followed-up dedicated multidisciplinary intervention....